Janneke van der Kamp starts as the new Chief Commercial Officer (CCO) of Grünenthal on March first 2023. She succeeds Mark Fladrich, who retired on February 28, 2023. Janneke van der Kamp joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation.
Our hearts go out to all those affected by the devastating earthquake that struck Türkiye and Syria this week. The loss of life and property is tragic, and our thoughts are with the people and communities affected by this disaster. Many of our colleagues have family and friends in the region. We stand by you during this difficult time.
In the face of such hardship, we must come together to support those in need. Grünenthal has donated €250,000 to support relief efforts in the affected areas.
We encourage all of our friends, colleagues, and partners to consider donating to the relief effort in any way they can.
Grünenthal relies on solar power for its corporate headquarters
Our Aachen R&D and production site is soon home to the region's largest solar power plant. With over 4.000 solar panels, we will generate enough energy to power 500 households. Our goal is to reach net zero emissions by 2030, and this solar power plant will play a key role in reducing up to 366 tonnes of CO2 annually.
Learn more about our initiatives to reduce our environmental footprintGrünenthal announces Joint Venture Collaboration with Kyowa Kirin International for established medicines portfolio with sales of ~€200 million.
The transaction combines Grünenthals unrivalled expertise in pain management with Kyowa Kirin’s portfolio of valuable medicines anchored in pain management. Grünenthal intends to acquire the full portfolio at the beginning of 2026.
Grünenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolioGrünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.
Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)4,500 dedicated employees – 75 years of experience in developing innovative medicines – a fully integrated setup including R&D and five manufacturing sites.
These are some of the key figures that have helped us become the leading pain management company in Europe and Latin America.
For the latest insights into our people, our products and our ambitious plans to move closer to our vision of a worldfreeofpain, check out the... Grünenthal Report 2021/2022
Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.
Join forces.
Make an impact.
Innovate for a world free of pain.
